Sector News

3M divests most of its drug-delivery business in $650-million deal

December 17, 2019
Chemical Value Chain

3M’s rumored divestiture of most of its drug-delivery business became a reality on 12 December, but the haul was far less than the one billion dollars that Bloomberg put out there earlier in the week.

The St. Paul, MN–based conglomerate entered into an agreement to sell substantially all of its drug-delivery business to an affiliate of Altaris Capital Partners LLC (New York) for approximately $650 million in total consideration, including cash, an interest-bearing security and a 17% non-controlling interest in the new company.

The 3M business is a global leader in drug delivery that partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using inhalation, transdermal, micro-needle and conventional drug-delivery technologies. 3M will retain its transdermal drug delivery components business. The business that is being divested has annual global sales of approximately $380 million.

“The drug delivery business is a leading provider of transdermal and inhalation delivery technologies,” said Michael Roman, 3M Chairman and CEO in a prepared statement. “This transaction will allow us to focus more resources on our core healthcare business as well as retain a share in the value of the drug-delivery business as it grows over the coming years.”

Buying and selling companies is more or less a core business activity of companies organized like 3M, writes Lee Schafer in the Minneapolis-based Star Tribune. In October, 3M paid approximately $6.7 billion, including assumption of debt, to acquire Acelity, which specializes in advanced wound-care and surgical products under the KCI brand. Although 3M has taken a hit on the stock market this year, declining about 19%, according to Bloomberg, the $33 billion company doesn’t need the money from the sale, writes Schafer. “It had $1.7 billion of free cash flow just in its most recent full quarter.”

So why sell a business that is a solid performer? “It could be as simple as it’s worth more to somebody else,” opines Shafer. “The buyer gets a business that’s worth more to them. The seller gets to take the money from the sale and invest it in opportunities that generate higher returns,” he writes. The proverbial win-win.

The transaction is subject to customary closing conditions and regulatory approvals. 3M said that it expects to close on the deal in the first half of 2020.

By Norbert Sparrow

Source: Plastics Today

comments closed

Related News

June 3, 2023

Chemours, DuPont, and Corteva reach comprehensive PFAS settlement with U.S. Water Systems

Chemical Value Chain

The Chemours Company (NYSE: CC), DuPont de Nemours, Inc. (NYSE: DD) and Corteva, Inc. (NYSE: CTVA) (the “companies”) today announced they have reached an agreement in principle to comprehensively resolve all PFAS-related drinking water claims of a defined class of public water systems that serve the vast majority of the United States population.

June 3, 2023

Storing hydrogen in coal may help power clean energy economy

Chemical Value Chain

The quest to develop hydrogen as a clean energy source that could curb our dependence on fossil fuels may lead to an unexpected place — coal. A team of Penn State scientists found that coal may represent a potential way to store hydrogen gas, much like batteries store energy for future use, addressing a major hurdle in developing a clean energy supply chain.

June 3, 2023

Soda ash producer WE Soda plans IPO, London share listing

Chemical Value Chain

WE Soda (London), a major producer of soda ash, said it intends to launch an IPO and apply to list its shares on the main market of the London Stock Exchange. The company, wholly owned by industrial conglomerate the Ciner Group (Istanbul, Turkey), said it is the world’s largest producer of natural soda ash.

How can we help you?

We're easy to reach